作 者: (荀培); (韩磊); (宋春青); (都玮); (张颖); (陆汉红); (李文文); (罗健);
机构地区: 首都医科大学大兴医院肿瘤内科,北京102600
出 处: 《中国医师杂志》 2017年第8期1176-1179,共4页
摘 要: 目的研究血小板计数(PLT)与乳腺癌患者病理特征及预后的关系,探寻乳腺癌预后评价的敏感性指标。方法回顾性分析1995年1月至2005年12月初诊的498例乳腺癌患者的临床资料,治疗前检测患者PLT,根据患者PLT高低分成A组(PLT〈150×10^9/L),B组[PLT(150-250)×10^9/L],C组(PLT〉250×10^9/L)三组,对PLT与患者病理特征进行相关性分析;采用Kaplan-Meier法及Cox风险比例模型对PLT对生存期的影响进行单因素分析及多因素分析。结果PLT计数与患者临床分期及T、N、M状态之间存在正相关(Pearson系数〉0,P〈0.05),PLT计数与生存期存在负相关(Pearson系数=-0.583,P〈0.05),A组、B组、C组生存期比较差异有统计学意义(P=0.018);Cox风险比例模型多因素分析显示PLT为影响患者生存期的独立因素(OR=2.256,P〈0.05)。结论乳腺癌患者病情加重与PLT升高相关,而PLT升高与生存期呈负相关,PLT对乳腺癌患者预后有预测作用。 Objective To investigate relationship of platelet (PLT) count with clinicopathological features and prognosis of patients with breast cancer, and explore the susceptibility index to evaluate progno- sis of patients with breast cancer. Methods A retrospective analysis of clinical data of 498 patients with breast cancer in January 1995 to December 2005 was carried out. PLT count was tested. Those patients were divided into group A (PLT〈150×10^9/L), group B[ ( 150 -250)×10^9/L], and group C ( PLT 〉 250×10^9/L) according to PLT count level. The relationship of platelet count with clinicopathological fea- tures was analyzed. Kaplan-Meier and Cox proportional hazards model were used for univariate analysis and multivariate analysis of PLT impact on survival time. Results There was positively correlated between PLT count and clinieopathologieal features ( Pearson coefficient 〉 0, P 〈 0. 05 ). There was negative correlated between PLT count and survival time ( Pearson coefficient = - 0. 583, P 〈 0. 05 ). The survival time of groups A, B and C were significantly different (P = 0. 018 ). Cox proportional hazards model multi-factor a- nalysis showed that PLT count was an independent factors affecting survival time ( OR = 2. 256, P 〈 0. 05 ). Conclusions Patients with breast cancer associated with increased emphasis and PLT count. PLT count had negative correlation with survival time. PLT count could be a susceptible index to predict the prognosis of patients with breast cancer.